Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

AstraZeneca details growth strategy

BC Staff
March 22, 2013 12:59 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said at an investor day on Thursday that it is aiming to double its Phase III pipeline by 2016 and will focus small and large molecule R&D on three core areas: respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and cancer. Pascal Soriot, who took over as CEO in October, said the pharma is aiming to create a portfolio with specialty care products to balance AstraZeneca's expertise in primary care.

AstraZeneca also is aiming to return to growth by focusing its investment and resources on five areas, including emerging markets and Japan. The pharma said it believes it can "significantly exceed" consensus estimates for 2018 revenues of $21.5 billion (see BioCentury, Nov. 5, 2012). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article